IGMS vs. CYRX, AUPH, ZNTL, XNCR, AMPH, AMRX, RCKT, CPRX, ZLAB, and GLPG
Should you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Cryoport (CYRX), Aurinia Pharmaceuticals (AUPH), Zentalis Pharmaceuticals (ZNTL), Xencor (XNCR), Amphastar Pharmaceuticals (AMPH), Amneal Pharmaceuticals (AMRX), Rocket Pharmaceuticals (RCKT), Catalyst Pharmaceuticals (CPRX), Zai Lab (ZLAB), and Galapagos (GLPG). These companies are all part of the "pharmaceutical preparations" industry.
Cryoport (NASDAQ:CYRX) and IGM Biosciences (NASDAQ:IGMS) are both small-cap transportation companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.
Cryoport currently has a consensus price target of $18.25, suggesting a potential upside of 77.53%. IGM Biosciences has a consensus price target of $17.89, suggesting a potential upside of 114.75%. Given Cryoport's stronger consensus rating and higher probable upside, analysts clearly believe IGM Biosciences is more favorable than Cryoport.
Cryoport has higher revenue and earnings than IGM Biosciences. Cryoport is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
Cryoport has a net margin of -50.17% compared to Cryoport's net margin of -11,255.25%. IGM Biosciences' return on equity of -15.19% beat Cryoport's return on equity.
92.9% of Cryoport shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 10.1% of Cryoport shares are owned by insiders. Comparatively, 57.0% of IGM Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Cryoport received 175 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 65.21% of users gave Cryoport an outperform vote while only 48.84% of users gave IGM Biosciences an outperform vote.
In the previous week, IGM Biosciences had 4 more articles in the media than Cryoport. MarketBeat recorded 6 mentions for IGM Biosciences and 2 mentions for Cryoport. IGM Biosciences' average media sentiment score of 1.11 beat Cryoport's score of 0.62 indicating that Cryoport is being referred to more favorably in the media.
Cryoport has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.
Summary
Cryoport beats IGM Biosciences on 11 of the 18 factors compared between the two stocks.
Get IGM Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IGM Biosciences Competitors List
Related Companies and Tools
